Gernot P. Tilz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gernot P. Tilz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Ulrike Demel
Clinical Immunology, Medical University of Graz, Graz, Austria
3 shared publicationsAlbin Hermetter
Technical University of Graz, Graz, Austria
2 shared publicationsChristian Faschinger
Medical University of Graz
2 shared publicationsMarco Wiltgen
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
2 shared publicationsUlrike Demel
2 shared publicationsAlbin Hermetter
1 shared publication
Latest Publications
- 23 December 2010
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 155 (2) , 167-179
On the Occurrence of the Diabetes-Associated Antigen GAD 65 in Human Sera
Background: Glutamic acid decarboxylase (GAD 65) is involved as an antigen in diabetes mellitus type 1 and is generally considered to be located intracellularly in pancreas β-cells. In this study we demonstrate its appearance in 64 human sera samples representing a cross-section of a blood bank. Method: The proof of GAD 65 in sera was done using an enzyme-linked immunosorbent assay (ELISA) setup where it was detected by interaction with corresponding antibodies labeled with an enzyme. The enzyme catalyzes a substrate reaction, resulting in a change of color, that is used for the quantitative evaluation of the antigen-antibody interaction. Result: The measurements showed that GAD 65 exists in various amounts in the sera of blood donors, with an average concentration of 58.00 ng/ml. The correlation analysis of samples stored at –80°C and at room temperature demonstrates the stability of GAD 65 at room temperature. The correlation coefficient between the GAD 65 concentrations of samples stored at room temperature and of the same samples after 1 week shows that the molecule remains stable. Conclusion: Our results encourage us to propose antigen GAD 65, due to its frequency in human sera in different concentrations and its stability, as a biomarker for the early diagnosis of type 1 diabetes and related inflammations.
- 23 December 2010
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 155 (2) , 167-179
On the Occurrence of the Diabetes-Associated Antigen GAD 65 in Human Sera
Background: Glutamic acid decarboxylase (GAD 65) is involved as an antigen in diabetes mellitus type 1 and is generally considered to be located intracellularly in pancreas β-cells. In this study we demonstrate its appearance in 64 human sera samples representing a cross-section of a blood bank. Method: The proof of GAD 65 in sera was done using an enzyme-linked immunosorbent assay (ELISA) setup where it was detected by interaction with corresponding antibodies labeled with an enzyme. The enzyme catalyzes a substrate reaction, resulting in a change of color, that is used for the quantitative evaluation of the antigen-antibody interaction. Result: The measurements showed that GAD 65 exists in various amounts in the sera of blood donors, with an average concentration of 58.00 ng/ml. The correlation analysis of samples stored at –80°C and at room temperature demonstrates the stability of GAD 65 at room temperature. The correlation coefficient between the GAD 65 concentrations of samples stored at room temperature and of the same samples after 1 week shows that the molecule remains stable. Conclusion: Our results encourage us to propose antigen GAD 65, due to its frequency in human sera in different concentrations and its stability, as a biomarker for the early diagnosis of type 1 diabetes and related inflammations.
- Open Access
- 1 February 2010
- Published by Walter de Gruyter GmbH in Pteridines
- Vol. 21 (1) , 22-28
Experiences with the SELDI-TOF Method for the Detection of the Diabetes Associated Antigen GAD 65 in the Peripheral Blood of Patients with Diabetes and Inflammation
The treatment of diabetes mellitus type 1 is a major challenge in health care. The diabetes associated antigen Glutamic Acid Decarboxylase (GAD 65) has been described as strictly intracellular. However an intracellular antigen would never have access to the immune system. In a previous study with the high sensitive fluorescence correlation spectroscopy (FCS), we detected the GAD 65 antigen in the sera of patients with type 1 diabetes and related autoimmune diseases. FCS is a time consuming measurement procedure and very sensitive to disturbance, which makes unsuitable for a routine screening of the patient sera for GAD 65. Since the measured GAD 65 concentrations were surprisingly high (2.65 microgram/ml) and therefore within the detection range of less sensitive methods, in this study we used the SELDI-TOF (Surface enhanced laser desorption ionisation - time of flight) technique to confirm the FCS results in view of an early diabetes diagnosis. For this purpose we developed an array with the SELDI-TOF method and analysed 4 patient sera (2 diabetes and 2 controls) in a pilot experiment. For one diabetes serum, we found some evidence for the diabetic antigen GAD 65 in the mass spectra in a peak close to albumin with a molecular weight of 65 kDa. The 3 other samples remained negative. Because of the higher concentration of albumin in the sera, a peak evaluation in regard of GAD 65 was difficult and not reliable in this setup. Troubles and experiences with SELDI-TOF for the detection of GAD 65 are discussed.
- 1 February 2010
- Published by Walter de Gruyter GmbH in Pteridines
- Vol. 21 (1) , 22-28
Open AccessExperiences with the SELDI-TOF Method for the Detection of the Diabetes Associated Antigen GAD 65 in the Peripheral Blood of Patients with Diabetes and Inflammation
The treatment of diabetes mellitus type 1 is a major challenge in health care. The diabetes associated antigen Glutamic Acid Decarboxylase (GAD 65) has been described as strictly intracellular. However an intracellular antigen would never have access to the immune system. In a previous study with the high sensitive fluorescence correlation spectroscopy (FCS), we detected the GAD 65 antigen in the sera of patients with type 1 diabetes and related autoimmune diseases. FCS is a time consuming measurement procedure and very sensitive to disturbance, which makes unsuitable for a routine screening of the patient sera for GAD 65. Since the measured GAD 65 concentrations were surprisingly high (2.65 microgram/ml) and therefore within the detection range of less sensitive methods, in this study we used the SELDI-TOF (Surface enhanced laser desorption ionisation - time of flight) technique to confirm the FCS results in view of an early diabetes diagnosis. For this purpose we developed an array with the SELDI-TOF method and analysed 4 patient sera (2 diabetes and 2 controls) in a pilot experiment. For one diabetes serum, we found some evidence for the diabetic antigen GAD 65 in the mass spectra in a peak close to albumin with a molecular weight of 65 kDa. The 3 other samples remained negative. Because of the higher concentration of albumin in the sera, a peak evaluation in regard of GAD 65 was difficult and not reliable in this setup. Troubles and experiences with SELDI-TOF for the detection of GAD 65 are discussed.
- 16 December 2009
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 152 (2) , 184-194
The Diabetic Antigen Glutamic Acid Decarboxylase (GAD 65) in the Human Peripheral Blood
Background: Glutamic acid decarboxylase (GAD 65) is a diabetes-associated antigen which is generally considered to be strictly intracellular. In order to better understand autoimmunity, this study demonstrates the appearance of GAD 65 in the peripheral human blood and presents implications for the diagnosis and therapy of some autoimmune diseases. Methods: The GAD 65 molecules are detected by their interaction with monoclonal antibodies labeled with dyes in an experimental setup with fluorescence correlation spectroscopy (FCS). These interactions result in changes in Brownian motion measured as fluorescence fluctuations. Sera from 153 patients with diabetes mellitus type 1 and controls were investigated. To enable the representation of the molecule as a model for further discussions, we present structural visualizations of its hydrophobic properties, leading to possible interactions with the cell membrane lipids and epitope locations. Results: The GAD65 antigen could be measured with a sensitivity of 2.65 µg/ml in ‘clean systems’ resulting from spiking experiments and human sera. The GAD 65 antigen could be identified in 8 patient sera: 4 children with diabetes mellitus type 1 and 4 adults initially taken as controls but who retrospectively showed signs of autoimmunity. Conclusion: We conclude that these findings are of significance for the concept of autoimmunity, i.e. in an initial step the immune system is primed by its accessibility to GAD 65. Our experimental results may also be important for the therapy of diabetes mellitus type 1 and other autoimmune diseases by the passive administration of GAD 65 antibodies.
- 16 December 2009
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 152 (2) , 184-194
The Diabetic Antigen Glutamic Acid Decarboxylase (GAD 65) in the Human Peripheral Blood
Background: Glutamic acid decarboxylase (GAD 65) is a diabetes-associated antigen which is generally considered to be strictly intracellular. In order to better understand autoimmunity, this study demonstrates the appearance of GAD 65 in the peripheral human blood and presents implications for the diagnosis and therapy of some autoimmune diseases. Methods: The GAD 65 molecules are detected by their interaction with monoclonal antibodies labeled with dyes in an experimental setup with fluorescence correlation spectroscopy (FCS). These interactions result in changes in Brownian motion measured as fluorescence fluctuations. Sera from 153 patients with diabetes mellitus type 1 and controls were investigated. To enable the representation of the molecule as a model for further discussions, we present structural visualizations of its hydrophobic properties, leading to possible interactions with the cell membrane lipids and epitope locations. Results: The GAD65 antigen could be measured with a sensitivity of 2.65 µg/ml in ‘clean systems’ resulting from spiking experiments and human sera. The GAD 65 antigen could be identified in 8 patient sera: 4 children with diabetes mellitus type 1 and 4 adults initially taken as controls but who retrospectively showed signs of autoimmunity. Conclusion: We conclude that these findings are of significance for the concept of autoimmunity, i.e. in an initial step the immune system is primed by its accessibility to GAD 65. Our experimental results may also be important for the therapy of diabetes mellitus type 1 and other autoimmune diseases by the passive administration of GAD 65 antibodies.
- 1 March 2007
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 157 (5-6) , 122-129
Insights into molecular medicine: Development of new diagnostic and prognostic parameters
In der Molekularen Medizin versucht man Krankheiten auf molekularer Ebene zu verstehen. Beispiele dafür sind die Analyse von Immunkomplexen sowie Rezeptor–Antirezeptor Verbindungen in der Klinischen Medizin. Entzündungen und Autoimmunreaktionen führen zu strukturelle Änderungen bei einigen Serumproteinen, deren Nachweis und Analyse neue Perspektiven für die Diagnose, Prognose, Therapie und Verlauf ermöglicht. Die moderne Medizin benötigt neue Technologien mit hoher Empfindlichkeit, Spezifität und Anwendbarkeit. Zum ersten Mal in Österreich kombinieren wir Fluoreszenz Korrelations-Spektroskopie (FCS), Surface-enhanced Laser Desorption/Ionisation Massenspektroskopie (SELDI-TOF) mit Computer gestützten Methoden der Molekularen Modellierung und Visualisierung. Experimentelle und Computer gestützte Methoden werden kombiniert, so dass die experimentellen und klinischen Daten auf der molekularen Ebene interpretiert werden können und umgekehrt neue Ansätze für erweiterte Untersuchungen gefunden werden. Wir führen die Kombination von diversen immunochemischen und theoretischen Methoden an geeigneten Medien wie Augenkammerwasser, Serum und hochgereinigte biologische Substanzen aus. Diese enthalten diverse Proteine, welche durch Tumor bedingte Enzyme und Entzündungsprodukte strukturell verändert wurden und dadurch einen verlässlichen Hinweis auf Erkrankungen geben können. Nachteile der erwähnten Technologien sind durch Multiplexing überwindbar. So konnten wir mittels SELDI-TOF Albumin im Augenkammerwasser nachweisen und wir erreichten eine hohe Empfindlichkeit beim Nachweis des Goodpasture Antikörpers mittels FCS. Die Resultate der Strukturanalyse von Albumin und Kollagen IV unter normalen Bedingungen dienen als Standard für zukünftige Untersuchungen. Software für die Strukturanalyse wurde bei uns entwickelt und die Ergebnisse werden hier anschaulich präsentiert. Die Kombination dieser Technologien ergibt neue Perspektiven für Diagnose and Therapie bestimmter Krankheiten. Da die verwendeten Technologien neu sind, sollte der wissenschaftlich interessierte Leser über die Möglichkeiten informiert werden. Molecular medicine leads us towards an understanding of some diseases at the molecular level. Examples are the analysis of immune complexes and receptor – anti receptor compounds used in clinical medicine. Structural changes of some serum proteins occur in inflammation, neoplasia and autoimmunity. The detection and analysis of such structural modifications may offer a new field for the diagnosis, prognosis and therapy of some diseases. Modern medicine requires new technologies with high sensitivity, specificity and applicability. For the first time in Austria we have combined fluorescence correlation spectroscope (FCS), surface enhanced laser desorption ionisation – time of flight (SELDI-TOF) and the molecular modelling and visualization system according to the computer enhanced programs. Experimental and computational methods are combined in such a way that clinical data can be interpreted by theoretical methods at a molecular level or vice versa, the computational output delivers input for new investigations. One method brings us single results. In view of the spectrum of parameters relevant to clinical entities, multiplexing is a new way of development. Since the technologies are new, the scientifically interested reader should be informed about the matters arising.
- 1 March 2007
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 157 (5-6) , 122-129
Insights into molecular medicine: Development of new diagnostic and prognostic parameters
In der Molekularen Medizin versucht man Krankheiten auf molekularer Ebene zu verstehen. Beispiele dafür sind die Analyse von Immunkomplexen sowie Rezeptor–Antirezeptor Verbindungen in der Klinischen Medizin. Entzündungen und Autoimmunreaktionen führen zu strukturelle Änderungen bei einigen Serumproteinen, deren Nachweis und Analyse neue Perspektiven für die Diagnose, Prognose, Therapie und Verlauf ermöglicht. Die moderne Medizin benötigt neue Technologien mit hoher Empfindlichkeit, Spezifität und Anwendbarkeit. Zum ersten Mal in Österreich kombinieren wir Fluoreszenz Korrelations-Spektroskopie (FCS), Surface-enhanced Laser Desorption/Ionisation Massenspektroskopie (SELDI-TOF) mit Computer gestützten Methoden der Molekularen Modellierung und Visualisierung. Experimentelle und Computer gestützte Methoden werden kombiniert, so dass die experimentellen und klinischen Daten auf der molekularen Ebene interpretiert werden können und umgekehrt neue Ansätze für erweiterte Untersuchungen gefunden werden. Wir führen die Kombination von diversen immunochemischen und theoretischen Methoden an geeigneten Medien wie Augenkammerwasser, Serum und hochgereinigte biologische Substanzen aus. Diese enthalten diverse Proteine, welche durch Tumor bedingte Enzyme und Entzündungsprodukte strukturell verändert wurden und dadurch einen verlässlichen Hinweis auf Erkrankungen geben können. Nachteile der erwähnten Technologien sind durch Multiplexing überwindbar. So konnten wir mittels SELDI-TOF Albumin im Augenkammerwasser nachweisen und wir erreichten eine hohe Empfindlichkeit beim Nachweis des Goodpasture Antikörpers mittels FCS. Die Resultate der Strukturanalyse von Albumin und Kollagen IV unter normalen Bedingungen dienen als Standard für zukünftige Untersuchungen. Software für die Strukturanalyse wurde bei uns entwickelt und die Ergebnisse werden hier anschaulich präsentiert. Die Kombination dieser Technologien ergibt neue Perspektiven für Diagnose and Therapie bestimmter Krankheiten. Da die verwendeten Technologien neu sind, sollte der wissenschaftlich interessierte Leser über die Möglichkeiten informiert werden. Molecular medicine leads us towards an understanding of some diseases at the molecular level. Examples are the analysis of immune complexes and receptor – anti receptor compounds used in clinical medicine. Structural changes of some serum proteins occur in inflammation, neoplasia and autoimmunity. The detection and analysis of such structural modifications may offer a new field for the diagnosis, prognosis and therapy of some diseases. Modern medicine requires new technologies with high sensitivity, specificity and applicability. For the first time in Austria we have combined fluorescence correlation spectroscope (FCS), surface enhanced laser desorption ionisation – time of flight (SELDI-TOF) and the molecular modelling and visualization system according to the computer enhanced programs. Experimental and computational methods are combined in such a way that clinical data can be interpreted by theoretical methods at a molecular level or vice versa, the computational output delivers input for new investigations. One method brings us single results. In view of the spectrum of parameters relevant to clinical entities, multiplexing is a new way of development. Since the technologies are new, the scientifically interested reader should be informed about the matters arising.
- Open Access
- 1 January 2006
- Published by Science Publications in American Journal of Immunology
- Vol. 2 (1) , 12-18
Introduction of Three Complementary Technologies into Clinical Medicine: Development of New Diagnostic and Prognostic Parameters
Introduction of Three Complementary Technologies into Clinical Medicine: Development of New Diagnostic and Prognostic Parameters
- 1 January 2006
- Published by Science Publications in American Journal of Immunology
- Vol. 2 (1) , 12-18
Open AccessIntroduction of Three Complementary Technologies into Clinical Medicine: Development of New Diagnostic and Prognostic Parameters
Introduction of Three Complementary Technologies into Clinical Medicine: Development of New Diagnostic and Prognostic Parameters
- 1 January 1996
- Published by Taylor & Francis in Hematology
- Vol. 1 (2) , 141-154
Soluble Receptors for Tumor Necrosis Factor and Neopterin as Parameters of Cell-Mediated Immune Activation
Tumor necrosis factor-α is a pleiotropic cytokine which is capable of inducing numerous immunological and biochemical changes in target cells and tissues, Soluble tumor necrosis factor-α receptors function to modulate the biological properties of tumor necrosis factor-α by enhancing or counteracting its action. In various pathologic states the production and release of soluble tumor necrosis factor receptors may mediate host response and determine the course and outcome of disease by the interaction with tumor necrosis factor-α and competing with cell surface receptors. The actual and forthcoming research of soluble tumor necrosis factor receptors in body fluids such as plasma or serum is a new tool to gain information about immune processes and is providing valuable insight into a variety of pathological conditions. In various diseases concentrations of sTNF-Rs correlate strongly with levels of neopterin, large amounts of which being released from human monocytes/macrophages upon stimulation with interferon-γ. Like neopterin, sTNF-Rs levels show high accuracy in the follow-up and prognosis of various diseases and correlate with the clinical stage and the progression of human immunodeficiency virus infection and sepsis. In cancer and autoimmune diseases, measurement of sTNF-Rs and neopterin provides useful information for monitoring. The quantification of sTNF-Rs and neopterin concentrations often provide even superior information than that obtained with classical disease markers, probably due to the direct involvement of the “interferon-γ/tumor necrosis factor-α system” in the pathogenetic mechanisms of the diseases. Data imply that measurement of sTNF-Rs, especially of the 75kD-type, is a useful adjunct for quantification of the Th-1 type immune response, sharing many characteristics with neopterin.
- 1 January 1996
- Published by Taylor & Francis in Hematology
- Vol. 1 (2) , 141-154
Soluble Receptors for Tumor Necrosis Factor and Neopterin as Parameters of Cell-Mediated Immune Activation
Tumor necrosis factor-α is a pleiotropic cytokine which is capable of inducing numerous immunological and biochemical changes in target cells and tissues, Soluble tumor necrosis factor-α receptors function to modulate the biological properties of tumor necrosis factor-α by enhancing or counteracting its action. In various pathologic states the production and release of soluble tumor necrosis factor receptors may mediate host response and determine the course and outcome of disease by the interaction with tumor necrosis factor-α and competing with cell surface receptors. The actual and forthcoming research of soluble tumor necrosis factor receptors in body fluids such as plasma or serum is a new tool to gain information about immune processes and is providing valuable insight into a variety of pathological conditions. In various diseases concentrations of sTNF-Rs correlate strongly with levels of neopterin, large amounts of which being released from human monocytes/macrophages upon stimulation with interferon-γ. Like neopterin, sTNF-Rs levels show high accuracy in the follow-up and prognosis of various diseases and correlate with the clinical stage and the progression of human immunodeficiency virus infection and sepsis. In cancer and autoimmune diseases, measurement of sTNF-Rs and neopterin provides useful information for monitoring. The quantification of sTNF-Rs and neopterin concentrations often provide even superior information than that obtained with classical disease markers, probably due to the direct involvement of the “interferon-γ/tumor necrosis factor-α system” in the pathogenetic mechanisms of the diseases. Data imply that measurement of sTNF-Rs, especially of the 75kD-type, is a useful adjunct for quantification of the Th-1 type immune response, sharing many characteristics with neopterin.